DOCKET NO.: L0461.70047US0

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Valerie Martelange et al.

7,001,999 B1

Serial No.:

09/183,789

Confirmation No.:

3523

Filed:

October 30, 1998

For:

TUMOR ASSOCIATED NUCLEIC ACIDS AND USES THEREFOR

Examiner:

Alana M. Harris

Art Unit:

1642

#### **CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop Certificate of Correction, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 24th day of February, 2006.

Melissa L.B. Lyons

#### Mail Stop Certificate of Correction

**Commissioner For Patents** P.O. Box 1450 Alexandria, VA 22313-1450

Certificate

Sir:

MAR 0 1 2006

Transmitted herewith are the following documents:

of Correction

- Request for Certificate of Correction Under 37 C.F.R. § 1.322
- **Certificate of Correction Form PTO-1050**
- Copy of pertinent page from U.S. Patent No. US 7,001,999 B1
- **Return Receipt Postcard**

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

> Respectfully submitted, Valeria Martelange et al., Applicant

By:

MaryDilys S. Anderson, Ph.D., Reg. No.: 52,560

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: L0461.70047US00

Date: February 24, 2006

**xNDDx** 



DOCKET NO.: L0461.70047US00

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Valerie Martelange et al.

Patent No.: Serial No.:

7,001,999 B1 09/183,789

Confirmation No.:

3523

Filed:

October 30, 1998

For:

TUMOR ASSOCIATED NUCLEIC ACIDS AND USES THEREFOR

Examiner:

Alana M. Harris

Art Unit:

1642

#### **CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop Certificate of Correction, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 24<sup>th</sup> day of February, 2006.

Melissa L.B. Lyons

**Mail Stop Certificate of Correction** 

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

# REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. §1.322 and § 1.323

Sir/Madam:

Patentees respectfully request the correction of an error found in the printing of the above-captioned patent. The correction made to claim 1 rectifies a typographical error made by the Patent Office. In claim 1, line 1, the phrase "a" should be replaced with "the complete" as indicated in the Examiner's amendment sent with the Notice of Allowance.

Patentees point out that the correction requested does not involve changes in the patent that constitute new matter or would require reexamination, and therefore, respectfully request that a certificate of correction be issued. Patentee encloses a copy of the patent page with the

Patent No.: US 7,001,999 B1 Page 2

error highlighted. A check is not enclosed. If a fee is deemed necessary, the fee may be charged to the account of the undersigned, Deposit Account No. 23/2825. Should any questions arise concerning the foregoing, please contact the undersigned at the telephone number listed below.

Respectfully submitted, Valeria Martelange et al., Applicant

By:

MaryDilys S. Anderson, Ph.D., Reg. No.: 52,560

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: L0461.70047US00

Date: February 24, 2006

xNDDx

### UNITED STATES PATENT AND TRADEMARK OFFICE

## **CERTIFICATE OF CORRECTION**

PATENT NO.: US 7,001,999 B1

DATE: February 21, 2006

INVENTORS: Valerie Martelange et al.

It is certified that the error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims:

Claim 1, lines 1 should read as shown below.

--An isolated nucleic acid molecule comprising the complete nucleic--

MAILING ADDRESS OF SENDER:

PATENT NO. US 7,001,999 B1

MaryDilys S. Anderson Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue Boston, Massachusetts 02210-2211

#### -continued

tgagaggtag	aaacttttct	catcaaactc	ctgagcacta	atctgcttac	agtatgagta	120
agttggcaaa	ggagcaaata	gtccatctcc	aggattttca	atatgtccct	tttttaagta	180
gtcaagatgt	ttttccactg	cagtctgtaa	gtaagagggt	acttgaagaa	tttcctgatg	240
atgatccatt	aagaaagaaa	ctaatcttcc	agcaagaagc	tcatcaagat	ccacttcttc	300
agcacagcat	aacacacatc	gagaaaaggt	atgnatcatc	aagtgacctc	gtacccattg	360
catcatggaa	gtttgggcat	atccaccatt	tttgactcat	tcggggaaat	catacgcatt	420
aaaagtttga	agcttctacg	antttggttg	ggggaa			456
	TH: 459 : DNA NISM: Homo a	sapiens				
<400> SEQU	ENCE: 47					
gaacttgtga	aaatcaataa	aatgatttat	tttatatatg	caaaatcaaa	atctctttgt	60
acactttaat	ttttgcaaat	tcatacaaac	ataacaatac	tgctccatat	asacttttgt	120
ataaacatta	aaggaaatat	acacatattt	tgttcttctt	gtgcttccaa	agcacagaat	180
gtataagtcc	atctgaagac	tttctatcat	cacatgcaag	aacaaatgtc	agaggttggg	240
ggcagcctca	agtgcacttt	gtaatgtctc	ttctcaaggt	actgaattag	gactcgtctt	300
ttaaaccttg	cggcttcctt	gatggtaaat	tcaacaaact	gtttcttcat	ctccagaggt	360
ccttgcactt	cttcaagcaa	aatgaaaatt	ctttcatatt	ttcgaccaaa	ctttcgaact	420

What is claimed is:

- 1. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:40, nucleotides 119–1831 of SEQ ID NO:38, and nucleotides 79–1659 of SEQ ID NO:43.
- 2. An expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter.
- 3. An isolated host cell transformed or transfected with the expression vector of claim 2.
- 4. A method for producing a polypeptide comprising expressing in an expression system the expression vector of claim 1, and isolating the polypeptide from the expression system.
- 5. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as SEQ ID NO:1.
- 6. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as nucleotides 119–1831 of SEQ ID NO:38.

- 7. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as SEQ ID NO:38.
  - 8. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as SEQ ID NO:40.
  - 9. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as nucleotides 79–1659 of SEQ ID NO:43.
- 10. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as SEQ ID NO:43.
  - 11. A method for producing a polypeptide comprising culturing the isolated host cell of claim 3, and isolating the polypeptide from the expression system.

\* \* \* \* \*